[1]
|
Rao, Q., et al. (2020) Clinical Benefits of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta Analysis. Hepatology International, 14, 765-775.
|
[2]
|
应倩, 汪源. 肝癌流行现况和趋势分析[J]. 中国肿瘤, 2020, 29(3): 185-191.
|
[3]
|
Tella, S.H., Mahipal, A., Kommalapati, A. and Jin, Z. (2019) Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date. OncoTargets and Therapy, 12, 10335-10342.
https://doi.org/10.2147/OTT.S214870
|
[4]
|
Siegel, A.B., Olsen, S.K., Magun, A. and Brown, R.S. (2010) Sorafenib: Where Do We Go from Here? Hepatology, 52, 360-369. https://doi.org/10.1002/hep.23633
|
[5]
|
Hodi, F.S., O’Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., et al. (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. The New England Journal of Medicine, 363, 711-723. https://doi.org/10.1056/NEJMoa1003466
|
[6]
|
Nishijima, T.F., Shachar, S.S., Nyrop, K.A. and Muss, H.B. (2017) Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. Oncologist, 22, 470-479.
https://doi.org/10.1634/theoncologist.2016-0419
|
[7]
|
Carretero-Gonzalez, A., Lora, D., Ghanem, I., Zugazagoitia, J., Castellano, D., Sepulveda, J.M., Lopez-Martin, J.A., et al. (2018) Analysis of Response Rate with ANTI PD-1/PD-L1 Monoclonal Antibodies in Advanced Solid Tumors: A Meta-Analysis of Randomized Clinical Trials. Oncotarget, 9, 8706-8715. https://doi.org/10.18632/oncotarget.24283
|
[8]
|
Boussiotis, V.A. (2016) Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. The New England Journal of Medicine, 375, 1767-1778. https://doi.org/10.1056/NEJMra1514296
|
[9]
|
Moskovitz, J., Moy, J. and Ferris, R.L. (2018) Immunotherapy for Head and Neck Squamous Cell Carcinoma. Current Oncology Reports, 20, 22. https://doi.org/10.1007/s11912-018-0654-5
|
[10]
|
Crispe, I.N. (2003) Hepatic T Cells and Liver Tolerance. Nature Reviews Immunology, 3, 51-62.
https://doi.org/10.1038/nri981
|
[11]
|
Karimi, M.H., Geramizadeh, B. and Malek-Hosseini, S.A. (2015) Tolerance Induction in Liver. International Journal of Organ Transplantation Medicine, 6, 45-54.
|
[12]
|
Tiegs, G. and Lohse, A.W. (2010) Immune Tolerance: What Is Unique about the Liver. Journal of Autoimmunity, 34, 1-6. https://doi.org/10.1016/j.jaut.2009.08.008
|
[13]
|
Carambia, A., Freund, B., Schwinge, D., Heine, M., Laschtowitz, A., Huber, S., et al. (2014) TGF-β-Dependent Induction of CD4+ CD25+ Foxp3+ Tregs by Liver Sinusoidal Endothelial Cells. Journal of Hepatology, 61, 594-599.
https://doi.org/10.1016/j.jhep.2014.04.027
|
[14]
|
Makarova-Rusher, O.V., Medina-Echeverz, J., Duffy, A.G. and Greten, T.F. (2015) The Yin and Yang of Evasion and Immune Activation in HCC. Journal of Hepatology, 62, 1420-1429. https://doi.org/10.1016/j.jhep.2015.02.038
|
[15]
|
Okusaka, T. and Ikeda, M. (2018) Immunotherapy for Hepatocellular Carcinoma:Current Status and Future Perspectives. ESMO Open, 3, e000455. https://doi.org/10.1136/esmoopen-2018-000455
|
[16]
|
Vandeven, N. and Nghiem, P. (2014) Pathogen-Driven Cancers and Emerging Immune Therapeutic Strategies. Cancer Immunology Research, 2, 9-14. https://doi.org/10.1158/2326-6066.CIR-13-0179
|
[17]
|
Lim, C.J., Lee, Y.H., Pan, L., Lai, L., Chua, C., Wasser, M., et al. (2018) Multidimensional Analyses Reveal Distinct Immune Microenvironment in Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut, 68, 916-927.
https://doi.org/10.1136/gutjnl-2018-316510
|
[18]
|
Lv, Y., Cui, M., Lv, Z., Lu, J., Zhang, X., Zhao, Z., et al. (2018) Expression and Significance of Peripheral Myeloid-Derived Suppressor Cells in Chronic Hepatitis B Patients. Clinics and Research in Hepatology and Gastroenterology, 42, 462-469. https://doi.org/10.1016/j.clinre.2018.04.002
|
[19]
|
Kondo, Y. and Shimosegawa, T. (2015) Significant Roles of Regulatory T Cells and Myeloid Derived Suppressor Cells in Hepatitis B Virus Persistent Infection and Hepatitis B Virus-Related HCCs. International Journal of Molecular Sciences, 16, 3307-3322. https://doi.org/10.3390/ijms16023307
|
[20]
|
El-Khoueiry, A.B., Melero, I., Crocenzi, T.S., Welling, T.H., Yau, T.C., Yeo, W.N., Chopra, A., et al. (2015) Phase I/II Safety and Antitumor Activity of Nivolumab in Patients with Advanced Hepatocellular Carcinoma (HCC): CA209-040. Journal of Clinical Oncology, 33, LBA101. https://doi.org/10.1200/jco.2015.33.18_suppl.lba101
|
[21]
|
El-Khoueiry, A.B., Sangro, B., Yau, T., Crocenzi, T.S., Kudo, M., Hsu, C., Kim, T.Y., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. https://doi.org/10.1016/S0140-6736(17)31046-2
|
[22]
|
Kudo, M., Finn, R.S., Qin, S., Han, K.H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.W., Han, G., Jassem, J., Blanc, J.F., Vogel, A., Komov, D., Evans, T.R.J., Lopez, C., Dutcus, C., Guo, M., Saito, K., Kraljevic, S., Tamai, T., Ren, M. and Cheng, A.L. (2018) Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. The Lancet, 391, 1163-1173.
https://doi.org/10.1016/S0140-6736(18)30207-1
|
[23]
|
Finn, R.S., Ikeda, M., Zhu, A.X., Sung, M.W., Baron, A.D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., Pracht, M., Mamontov, K., Meyer, T., Kubota, T., Dutcus, C., Saito, K., Siegel, A.B., Dubrovsky, L., Mody, K. and Llovet, J.M. (2020) Phase Ib Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology, 38, 2960-2970. https://doi.org/10.1200/JCO.20.00808
|
[24]
|
Finn, R.S., Qin, S., Ikeda, M., Galle, P.R., Ducreux, M., Kim, T.Y., Kudo, M., Breder, V., Merle, P., Kaseb, A.O., Li, D., Verret, W., Xu, D.Z., Hernandez, S., Liu, J., Huang, C., Mulla, S., Wang, Y., Lim, H.Y., Zhu, A.X. and Cheng, A.L. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The New England Journal of Medicine, 382, 1894-1905. https://doi.org/10.1056/NEJMoa1915745
|
[25]
|
Xu, J., Shen, J., Gu, S., Zhang, Y., Wu, L., Wu, J., Shao, G., Zhang, Y., Xu, L., Yin, T., Liu, J., Ren, Z., Xiong, J., Mao, X., Zhang, L., Yang, J., Li, L., Chen, X., Wang, Z., Gu, K., Chen, X., Pan, Z., Ma, K., Zhou, X., Yu, Z., Li, E., Yin, G., Zhang, X., Wang, S. and Wang, Q. (2021) Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-Label, Phase II Trial. Clinical Cancer Research, 27, 1003-1011. https://doi.org/10.1158/1078-0432.CCR-20-2571
|
[26]
|
Zhang, T.-Q., et al. (2021) 946P Hepatic Artery Infusion Chemotherapy (HAIC) Combined with Apatinib and Camrelizumab for Hepatocellular Carcinoma (HCC) in BCLC Stage C: A Prospective, Single-Arm, Phase II Trial (TRIPLET Study). Annals of Oncology, 32, S825. https://doi.org/10.1016/j.annonc.2021.08.166
|